New York, May 06, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Liquid Biopsy Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product and Services ; ...
The integrated solution delivers an automated, end-to-end workflow for isolating circulating cell-free DNA (cfDNA), circulating cell-free RNA (cfRNA), circulating cell-free total nucleic acid (cfTNA), ...
Unlock the latest liquid biopsy market data. Explore growth drivers, precision oncology shifts, and the tech fueling ...
DUBLIN--(BUSINESS WIRE)--The "Liquid Biopsy Market: Market Size, Trends and Growth Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering. The future of the global liquid ...
Comprehensive Sequencing and Analysis of Circulating, Cell-Free DNA in Longitudinal Studies With the advent of liquid biopsy assays, it is now possible to monitor the treatment response of oncology ...
Our extensive research on the Liquid Biopsy (2024-2032) offers valuable insights for businesses. This comprehensive report delves into emerging trends, investment opportunities, technological ...
Researchers examining GI endoscopes after colonoscopy and esophagogastroduodenoscopy (EGD) procedures found a "startlingly high" rate of retained biopsy samples in the endoscope accessory channel or ...
The MarketWatch News Department was not involved in the creation of this content. Collaboration integrates the nRichDX Revolution Plus(TM) Sample Prep System with the Hamilton Microlab STAR(R) ...
Collaboration integrates the nRichDX Revolution Plus™ Sample Prep System with the Hamilton Microlab STAR ® platform, delivering automated, high-yield liquid biopsy workflows for cfDNA, cfRNA, cfTNA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results